Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Sakoulas
  NCT04411667		 RCTimmunoglobulin therapy standard of careCOVID 19 hospitalizedsome concern
17/17 inconclusive
  • inconclusive 81 % decrease in mechanical ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias

COVID-19 severe or critically meta-analysis

Raman
  CTRI/2020/06/026222		 RCTimmunoglobulin therapy standard of careCOVID-19 severe or criticallysome concern
50/50 suggested
  • suggested 35.4-fold increase in viral clearance ,viral clearance by day 14 with a moderate degree of certainty due to some concern in risk of bias
Gharebaghi
  IRCT20200501047259N1		 RCTimmunoglobulin therapy placeboCOVID-19 severe or criticallyNA
30/29 suggested
  • suggested 100 % decrease in deaths,death D28
Tabarsi
  IRCT20151227025726N2		 RCTimmunoglobulin therapy standard of careCOVID-19 severe or criticallysome concern
52/32 inconclusive
  • inconclusive 10 % increase in deaths,death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
  • inconclusive 49 % increase in mechanical ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
  • inconclusive 44 % decrease in ICU admission (PE) with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons